LensGen® Closes $5.9 Million Financing

Irvine, Calif., March 2, 2023 – LensGen, Inc., a clinical stage ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, announces the closing of a $5.9 million Bridge Financing.  The financing was led by the corporate venture investment arm of HOYA Group.

Recent News